Brief: Kancera Signs Letter Of Intent Agreement With Recardio For Licensing Of Kand567, Kand145
07/03/2025 07:05
March 7 (Reuters) - Kancera AB KANC.ST: SIGNS LETTER OF INTENT AGREEMENT WITH RECARDIO FOR LICENSING OF KAND567 AND KAND145 Source text: ID:nMFN4WTHDg Further company coverage: KANC.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novakand Pharma AB
See all newsBrief: Nasdaq Decides To Delist Novakand From First North Growth Market
Brief: Novakand Pharma Extends Peter Selin's CEO Employment
Brief: Novakand Board Proposes New Business Direction, Relisting
Brief: Novakand Pharma Evaluates Options After Decision Not To Execute Reverse Take Over
Brief: Nasdaq Rejects Novakand's Application For Continued Listing